CHO-Based Assay Kit

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology, March 2023
Volume 47
Issue 3
Pages: 12

Charles River’s HCP-ELISA kit is designed to increase the efficiency and efficacy of HCP assay development.

Charles River’s HCP-ELISA Kit

Charles River’s HCP-ELISA Kit

Charles River Laboratories’ enzyme-linked immunosorbent assay (ELISA) kit is designed for the detection and quantitation of residual host cell proteins (HCP) in Chinese hamster ovary (CHO)-based biotherapeutics. Building on the company’s HCP-GAPex service, the HCP–ELISA kit is designed to increase the efficiency and efficacy of HCP assay development.

The HCP–ELISA kit has a 96-well assay plate and has a time-to-result of approximately three hours. It leverages avian immunoglobulin Y antibodies as the primary detection technology, which are derived from specific-pathogen-free chicken eggs developed exclusively by AVS Bio.

Charles River Laboratories

Download Issue PDF
Articles in this issue
data web
Harnessing Technology to Ensure Drug Safety
Africa Studio/Stock.adobe.com – Variances and means are compared using F and T tests, respectively.
Justification of Using Weight Variation Instead of Content Uniformity for Release of Relevant OSD Forms
Excipients Impact Stability in mRNA-LNP Formulations
Excipients Impact Stability in mRNA-LNP Formulations
Shopping cart with medical ampoule, syringe and capsules on a blue background, copy space, top view. Concept of purchasing medicines, increasing drug prices. Vertical photo | Image Credit: © yaroslav1986 - Stock.adobe.com
Influencing Change in Drug Delivery
Intestine decorative model with pills on light blue background. Probiotics and prebiotics for microbiome intestine, healthy digestion concept. Top view, flat lay, copy space | Image Credit: © Elena - Stock.adobe.com
Frontrunner in Microbiome Therapeutics
Implementing Process Analytical Technology
Implementing Process Analytical Technology
omar/Stock.Adobe.com
Automated Inspection of Pre-filled Syringes and Biologics During Fill/Finish
Paulista/stock.adobe.com – For high-risk analytical procedures, control-chart monitoring of selected performance data can provide early warning of changes in performance.
Ongoing Analytical Procedure Performance Verification—Stage 3 of USP<1220>
Taking Steps Toward Supply Chain Continuity
Taking Steps Toward Supply Chain Continuity
Medicine, Healthcare And Medicine, Vaccination | Image Credit: © BillionPhotos.com - Stock.adobe.com
Keeping Europe’s Medicines Stocked
WEYO - STOCK.ADOBE.COM - The trends shaping the growth of the biologics outsourcing industry demand attention.
The Logistics of Outsourcing Biologics
Vaccine Development Builds on COVID-19 Breakthroughs
Vaccine Development Builds on COVID-19 Breakthroughs
Landkarte *** Europa | Image Credit: © beugdesign - Stock.adobe.com
EMA Guidance on Paediatric Investigation Plans
Outsourcing Still Vital
Outsourcing Still Vital
Retro classic typewriter from circa 1950s with sheet of paper and aged books on wooden desk front aquamarine wall background. Nostalgic writer's work place concept. Vintage old style filtered photo | Image Credit: © BrAt82 - stock.adobe.com
Feeling the Pinch
Recent Videos
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Behind the Headlines episode 6
Behind the Headlines episode 5
Related Content
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Orexo and Abera Partner to Develop Nasal Powder Vaccines

Feliza Mirasol
December 20th 2024
Article

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novo Nordisk to Establish New Production Facility for Rare Disease Therapies in Denmark with DKK 8.5 Billion Investment

Feliza Mirasol
December 17th 2024
Article

Novo Nordisk will use the DKK 8.5 billion (US$1.2 billion) to build a new modular and flexible production facility in Odense, Denmark, that will produce multiple products for rare diseases.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Novo Nordisk Gains Manufacturing Sites from Novo Holdings and Novavax while EC Approves Catalent Acquisition

Feliza Mirasol
December 11th 2024
Article

The European Commission has approved Novo Holdings' acquisition of Catalent, which includes the related sale of three manufacturing sites to Novo Nordisk, which is also acquiring the Czech Republic manufacturing site of Novavax for $200 million.

3D printed pills and drugs, future of medicine. 3D Printing Drugs In Pharmacies. Multi-colored, various drugs, pills, capsules. Pharmaceutical medical concept | Image Credit: © irissca - © irissca - stock.adobe.com

Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications

Gary Ritchie;Sharon Flank
December 10th 2024
Article

This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.